Cybin Stock Forum

Tang Capital 1,330,097 shares, 6.7%
$Cybin (CYBN.US)$
has options
nfa

$Cybin (CYBN.US)$
Cybin's Depression Drug Shows Perfect Response Rate, Advances to Pivotal Phase 3 with C$136M War Chest

$Cybin (CYBN.US)$
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Monday, 10th February at 9:48 pm
- Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder ("MDD") -
- PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND),...

$Cybin (CYBN.US)$ let's go CYBIN 👏👏 let's go CYBIN 👏👏

$Cybin (CYBN.US)$ you get a mushroom you get a mushroom we all get mushrooms!!! (by mushrooms I mean Washington's head on the dollar bill!

$Cybin (CYBN.US)$ Trump backs this company we have been waiting for this for to long you are gonna help billions of people!!!

$Cybin (CYBN.US)$ Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
1 MINUTE AGO, 12:07 PM EST
VIA BUSINESSWIRE
Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred pr...

$Cybin (CYBN.US)$
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Wednesday, 15th January at 12:07 pm
- Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred provider fo...

$Cybin (CYBN.US)$
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Monday, 13th January at 7:30 am
- Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder ("MDD") -
- Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD –
- Received U.S. Food and Drug Administration ("FDA") Breakthrough Therapy Designation ("BTD") for CYB003 for the Adjunc...